Insurers like Blue Cross Blue Shield of Massachusetts and Harvard Pilgrim Health Care are rolling back coverage for GLP-1 drugs prescribed for weight loss due to high costs, while maintaining coverage for diabetes. This shift places the financial burden on employers and patients, sparking outrage among advocates who now suggest that government intervention, such as an executive order, may be necessary to ensure equitable access.
The most-used peptide combinations, what the research actually says, and where to buy — one page, one email.
No spam. Unsubscribe anytime.